Sub: Outcome of 38th Annual General Meeting ("AGM") held on August 2, 2022
Ref: Disclosure/ submission pursuant to SEBI (Listing Obligations & Disclosure
Requirements), Regulations, 2015
With reference to the captioned subject, please find attached the following.
Summary of proceedings as required under Regulation 30, Part A of Schedule Ill of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.
Voting results as required under Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015.
Report of Scrutinizer dated August 2, 2022, pursuant to Section 108 of the Companies Act 2013 and Rule 20 (4) (xii) of the Companies (Management and Administration) Rules, 2014.
Please take note that the above referred documents are being uploaded on the website of the Company.
This is for your information and records.
Yours faithfully,
For Neuland Laboratories Limited
•,J,' :-'.,·'
�1HYDE1,,
Sarada Bhamidipati
Company Secretary_
Encl: As Above
Registered Office; l 1h Floor, (Sth Office Level), Phoenix IVY Building, Plot No; 573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India I CIN No. L85195TG1984PLC004393
NEULAND LABORATORIES LIMITED
Date of the AGM/EGM
02-08-2022
Total number of shareholders on record date
324S5
No. of shareholders present In the meeting either In person or through proxy:
Not Applicable
Promoters and Promoter Group:
Public:
Not Applicable
No. of Shareholders attended the meeting through Video Conferencing
Promoters and Promoter Group:
5
Public:
69
Resolution No.
1
Resolution required: (Ordinary/ Special)
ORDINARY - To receive, consider and adopt (a) the Audited Financial Statements of the Company for the financial year ended March 31, 2022, together with the reports of the Board of
Directors and the Auditors' thereon and (bl the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2022, together with the report of the
Auditors thereon.
WJ!ek-�promoter group are
��-··
·�
% of Votes Polled
% of Votes in
% of Votes
No. of shares held
on outstanding
favour on votes
against on votes
Category
Mode of Voting
No. of votes
shares
No. of Votes - in
No. of Votes -
polled
polled
Votes Abstained
(1)
polled (2)
(3)=[(2)/(1)]* 100
favour(4)
against(5)
(6)=[(4)/(2)]*100
(7)=[(5)/(2)]*100 Votes Invalid
E-Voting
4,493,721
96.7009
4,493,721
0
100.0000
0.0000
0
0
Poll
4,647,032
0
0.0000
0
0
0.0000
0.0000
0
0
Promoter and Promoter Group
Postal Ballot(if
.
applicable)
0
0.0000
0
0
0.0000
0.0000
0
0
:rotat
�
4.493,721
-0
. 100.POO(I
0.0000
(J
C
E-Votlng
1,600,796
51.8630
1,600,796
0
100.0000
0.0000
0
0
Poll
3,086,588
0
0.0000
0
0
0.0000
0.0000
0
0
Public- Institutions
Postal Ballot (if
applicable)
0
0.0000
0
0
0.0000
0.0000
0
0
'total
1A•
Sl.863
l.600,191
(J
�.OIJDII
0.llllll
(:
C
E-Voting
11,078
0.2174
10,972
106
99.0431
0.9568
0
3,392
Poll
5,095,269
2,893
0.0568
2,893
0
100.0000
0.0000
0
0
Public- Non Institutions
Postal Bailot(if
applicable)
II
!11!111111&!!1
0
0.0000
0
0
0.0000
-
0.0000
0
0
----
-
-
- ---- .--:-1
47,
- 9.865
�,_--...,_
.
---
•
-
Toltal.
DJm
U74.
till
99.141!1
D..:r.iffi
(l
3392
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 02 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2022 10:55:03 UTC.
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.